Biogen Pharmachem Industries Limited has announced a board meeting scheduled for February 3, 2026, to consider its Q3FY26 unaudited financial results. The company has formally notified BSE Limited about this meeting in compliance with regulatory requirements.

Board Meeting Details

The meeting agenda and key details are outlined below:

Meeting Agenda

The board will consider the following matters during the scheduled meeting:

• Approval and recording of unaudited financial results for the quarter and nine months ended December 31, 2025
• Any other business matters that the board may deem appropriate with necessary permissions

Regulatory Compliance

Biogen Pharmachem Industries Limited has issued this intimation pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was formally communicated to BSE Limited, where the company's shares are listed under scrip code 531752 and scrip ID BIOGEN.

Company Information

The company, formerly known as Sun Techno Overseas Limited, operates under CIN number L51100GJ1995PLC026702. Director Kelash Bunkar signed the official communication to the stock exchange on January 19, 2026, ensuring compliance with mandatory disclosure requirements for listed companies.

Biogen Pharmachem Industries Limited has fulfilled its regulatory compliance requirements by submitting the mandatory quarterly certificate under SEBI regulations for the third quarter of fiscal year 2026. The pharmaceutical company, listed on BSE with scrip code 531752, completed this submission on January 5, 2026.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. This regulation mandates listed companies to provide quarterly confirmations regarding the dematerialization of physical share certificates.

Certificate Confirmation

Satellite Corporate Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the compliance certificate. The certificate confirms adherence to standard regulatory requirements, including verification that securities are listed on stock exchanges and proper record maintenance procedures.

A significant aspect of this quarter's report is that no physical share certificates were received for dematerialization during Q3FY26. This indicates that shareholders did not submit any physical certificates for conversion to electronic form during the three-month period.

Company Information

Biogen Pharmachem Industries Limited operates under CIN L51100GJ1995PLC026702 and was formerly known as Sun Techno Overseas Limited. The company maintains its registered office at Shop No. 8, First Floor, Maker-1 Building, Jawahar Road, Rajkot-360001, Gujarat.

Regulatory Distribution

The certificate submission was distributed to relevant regulatory authorities and depositories as per standard compliance procedures:

• BSE Limited (primary listing exchange)
• National Securities Depository Limited (NSDL)
• Central Depository Services (India) Limited (CDSL)

This quarterly submission demonstrates the company's commitment to maintaining transparency and regulatory compliance in accordance with SEBI guidelines for listed entities.